Opioid Use Disorder
📧 Sign up to get email alerts when something new happens for Opioid Use Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-23Clinical Trial Update: reSET-O RCT (Randomized Controlled Trial) [NA]
Completion of the reSET-O randomized controlled trial for opioid use disorder with results posted on 2024-05-23.
-
CLINICAL_TRIALS withdrawal · 2024-05-22Clinical Trial Update: Buprenorphine Induction for Fentanyl Dependent Opioid Users [EARLY_Phase 1]
This early-phase 1 clinical trial evaluating buprenorphine induction for fentanyl-dependent opioid users has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-05-21Clinical Trial Update: Evaluation of a Patient-Centred, Multidisciplinary Opioid Tapering Program for Individuals With Chronic Non-Cancer Pain on Long Term Opioid Therapy [NA]
Completed clinical trial evaluating a patient-centered, multidisciplinary opioid tapering program for individuals with chronic noncancer pai…
-
CLINICAL_TRIALS trial_result · 2024-05-20Clinical Trial Update: Combining Pregabalin (LYRICA®) With Lofexidine (LUCEMYRATM) to Treat OPIOID Withdrawal [Phase 2]
Phase 2 trial evaluating the combination of pregabalin (Lyrica) and lofexidine (Lucemyra) for opioid withdrawal; results were posted after c…
-
CLINICAL_TRIALS research · 2024-05-17Clinical Trial Update: Community Opioid Innovation Network (JCOIN): TCU Clinical Research Center [NA]
This ClinicalTrials.gov entry shows ongoing recruitment for a Community Opioid Innovation Network trial at Texas Christian University focuse…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-10Clinical Trial Update: Translation and Validation of the COMM and ASI-SR
A clinical trial evaluating translation and validation of the Current Opioid Misuse Measure (COMM) and the Addiction Severity Index - Self-R…
-
CLINICAL_TRIALS trial_result · 2024-05-07Clinical Trial Update: Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics
A completed clinical trial evaluated how pregnancy alters buprenorphine pharmacokinetics and pharmacodynamics in people with opioid use diso…
-
CLINICAL_TRIALS trial_result · 2024-05-06Clinical Trial Update: KAP for Depression in Abstinent Opioid Users [Phase 2]
A Phase 2 clinical trial evaluating KAP for depression in abstinent opioid users was terminated, and results were posted on 2024-05-06.
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: Opioid Reduction Toolkit Reduces Opioids Prescribed and Consumed [Phase 4]
Phase 4 trial update shows an opioid reduction toolkit reduces opioids prescribed and consumed.
-
FDA approval · 2024-04-19FDA Approved: REZENOPY — Original Application (Scienture LLC)
FDA approved REZENOPY (naloxone hydrochloride) from Scienture LLC under an Original New Drug Application. It is approved as an emergency rev…
-
FDA approval · 2024-04-19FDA Approved: SUBLOCADE — Supplemental Application (Indivior Inc.)
FDA approves a supplemental application for SUBLOCADE (buprenorphine) by Indivior Inc., potentially updating the product’s labeling or indic…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery [NA]
A completed pilot clinical trial evaluating the nCAP Signal Relief Patch for patients undergoing hip or knee replacement surgeries; results …
-
CLINICAL_TRIALS trial_result · 2024-04-15Clinical Trial Update: Buprenorphine Loading in the Emergency Department [Phase 4]
Phase 4 trial update on buprenorphine loading in the emergency department for opioid-use disorder; study completed with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: Evaluating the Impact of the Bridge Clinic in Patients With Opioid Use Disorder [NA]
This document reports the completion of a Vanderbilt-led clinical trial evaluating the impact of a Bridge Clinic program on patients with op…
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: Stress Response in Opioid Use Disorder [NA]
Clinical trial update for stress response in opioid use disorder has completed; results posted in 2024.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application from Lannett Company for a buprenorphine/naloxone product, expanding access to a generic treatme…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE HCL AND NALOXONE HCL — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved the supplemental application for buprenorphine HCl and naloxone HCl from Amneal as a generic product for the treatment of opioi…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for a generic buprenorphine hydrochloride and naloxone hydrochloride dihydrate product to treat opio…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine from Actavis Pharma, Inc. under ANDA090819, granting regulatory clearance for this…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for a generic buprenorphine and naloxone product (buprenorphine hydrochloride and naloxone hydrochlo…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE — Supplemental Application (SpecGx LLC)
FDA approved a supplemental application for buprenorphine hydrochloride and naloxone hydrochloride dihydrate from SpecGx LLC.
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Dr.Reddys Laboratories Inc)
FDA approved a supplemental application for Buprenorphine and Naloxone from Dr. Reddy's Laboratories, enabling market authorization for this…
-
FDA approval · 2024-03-20FDA Approved: SUBOXONE — Supplemental Application (INDIVIOR INC.)
FDA approved a supplemental application for SUBOXONE (buprenorphine hydrochloride and naloxone hydrochloride) from Indivior Inc., related to…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE HYDROCHLORIDE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)
FDA approved a supplemental application for buprenorphine hydrochloride from PAI Holdings/PAI Pharma. This approval updates the product’s la…
-
FDA approval · 2024-03-20FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for buprenorphine and naloxone from Actavis Pharma, Inc., under an ANDA. This generic product is use…